Skip to main navigation Skip to search Skip to main content

Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C

  • G. Firneisz*
  • , P. L. Lakatos
  • , M. Horányi
  • , A. Pár
  • , Á Gógl
  • , M. Abonyi
  • , K. Dávid
  • , J. Fehér
  • , J. Gervain
  • , E. Nemesánszky
  • , Gy Tolvaj
  • , G. Horváth
  • , L. Telegdy
  • , A. Csepregi
  • , P. Ribiczey
  • , B. Büki
  • , E. Ibrányi
  • , Zs Ozsvár
  • , L. Pete
  • , L. Rókusz
  • H. Osztrogonác, F. Szalay
*Corresponding author for this work

Research output: Journal article (peer-reviewed) › Journal article

Abstract

Background: DPP IV is a cell surface ectoenzyme widely distributed in the human body. It has been implicated in T-cell activation, hepatocyte-extracellular-matrix interactions and fibroblast proliferation. Furthermore, upregulated CD26 expression has been found on the surface of human hepatoma cells transfected with hepatitis C virus (HCV) c-DNA. We examined the serum DPP IV activity in a large number of patients with chronic HCV infection in a cross-sectional study. We also investigated whether the activity differs from that in controls and depends upon the response to interferon (IFN) therapy. Methods: Serum DPP IV activity was measured by microplate-based (Multiskan-Plus-MKII, Labsystem) kinetic assay in 144 patients with chronic HCV infection. Seventy-four out of 144 patients (46 non-responders, 28 responders) were formerly treated with interferon. Sixty healthy blood donors served as controls. Gly-Pro-PNA (Bachem, Torrance, USA) was used as substrate. Results are expressed in nmol/ml/min (U/l). Shapiro-Wilk's test, Mann-Whitney U test and Spearman rank order correlation were used for statistical analysis. Results: Serum DPP IV activity was significantly higher (mean = 20.89 [s 9.6]) in patients with chronic HCV infection than in healthy controls (12.39 [2.76, P < 10-5]). The enzyme activities significantly differed in naive HCV-positive patients (22.2 [9.89, P < 10-5]) and non-responders (23.28 [9.57, P < 10-5]) from that in the healthy controls and also from that in responders (13.69 [4.21]). Correlation was found between DPP IV activity and AST (r = 0.44, P < 10-5), ALT (r = 0.44, P < 10-5), GGT (r = 0.41, P < 10-5) levels. Conclusion: Serum DPP IV activity seems to be an indicator of HCV induced liver injury. The activity may reflect the efficacy of interferon therapy.

Original languageEnglish
Pages (from-to)877-880
Number of pages4
JournalScandinavian Journal of Gastroenterology
Volume36
Issue number8
DOIs
Publication statusPublished - 2001
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CD26
  • Dipeptidyl peptidase IV
  • DPP IV
  • HCV
  • Hepatitis
  • Interferon

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C'. Together they form a unique fingerprint.

Cite this